What started as groundbreaking research at CU Anschutz has now become a major milestone in biotech innovation. Q32 Bio has announced the sale of its complement inhibitor ADX-097, a first-in-class therapeutic designed to precisely regulate the complement system—a key driver in autoimmune and inflammatory diseases. This advancement opens the door to new treatment possibilities for patients with high unmet medical needs.